Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) gained $2.23 to $35.62 last week after partner AbbVie Inc. (NYSE:ABBV) submitted an NDA to FDA for its all-oral regimen comprising ABT-450 plus AbbVie's Norvir ritonavir, ABT-267 and ABT-333 with and without ribavirin to treat HCV genotype 1 infection.
Enanta helped discover ABT-450, an HCV NS3/4A protease inhibitor.
QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY) fell $2.84 (84%) to $0.56 and A$0.56 (80%) to A$0.14 in Australia on Wednesday after FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 14-0 against approval of MoxDuo IR morphine/oxycodone to treat moderate to severe acute pain. The panel also voted unanimously that the company did not provide evidence that MoxDuo IR is safer than its individual components.
The product has a May 25 PDUFA date.
QRxPharma finished the week off $2.89 (85%) to $0.51 and down A$0.60 (85%) to A$0.11 in Australia.